Terms: = Ovarian cancer AND TPM3, ENSG00000143549, 7170 AND Treatment
2 results:
1. Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.
Xu X; Wang Y; Bryce NS; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW
Br J Cancer; 2021 Jul; 125(2):265-276. PubMed ID: 33981016
[TBL] [Abstract] [Full Text] [Related]
2. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line treatment of ovarian cancer: A Systematic Review and Meta-analysis.
Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
[TBL] [Abstract] [Full Text] [Related]
